Kintor Pharmaceutical Announces 18 June 2026 AGM; Seeks 20% Issuance Mandate and 10% Share Buy-Back Authority

Kintor Pharmaceutical Limited has issued a notice convening its Annual General Meeting (AGM) for 09:00 a.m. on 18 June 2026 at Unit 419, 20 Songbei Road, Suzhou Industrial Park, Jiangsu Province, PRC.

Key agenda items:

1. 2025 Financial Statements • Shareholders will be asked to receive and adopt the audited consolidated financial statements and the directors’ and independent auditor’s reports for the year ended 31 December 2025.

2. Board Composition and Remuneration • Re-election of Dr. Xiang Ni as Executive Director, and Mr. Yunfei Chen and Ms. Geqi Wei as Non-Executive Directors. • Authorisation for the board to determine directors’ remuneration.

3. Auditor Appointment • Proposal to appoint Rongcheng (Hong Kong) CPA Limited as auditor until the conclusion of the next AGM, with board-delegated authority to fix its remuneration.

4. General Mandates • Share Issuance: Directors seek approval to allot, issue, or deal with additional shares—excluding treasury shares—up to 20 % of the company’s issued share capital during the mandate period. • Share Buy-Back: Authority to repurchase up to 10 % of issued shares (excluding treasury shares) on the Hong Kong Stock Exchange or other recognised exchanges. • Extension Mandate: Shares repurchased under the buy-back mandate may be added to the 20 % issuance limit, effectively increasing the potential issuance headroom by the number of shares bought back.

Administrative details:

• All resolutions will be decided by poll in accordance with Hong Kong Listing Rules. • The share register will be closed from 15 June 2026 to 18 June 2026 (both days inclusive); transfers must be lodged by 16:30 on 12 June 2026 to qualify for attendance and voting. • Proxy forms must be submitted to Computershare Hong Kong Investor Services Limited no later than 09:00 a.m. on 16 June 2026.

As of the notice date (26 May 2026), the board comprises two Executive Directors (Dr. Youzhi Tong and Dr. Xiang Ni), two Non-Executive Directors (Mr. Yunfei Chen and Ms. Geqi Wei), and three Independent Non-Executive Directors (Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung, and Prof. Liang Tong).